Swedish Medtech Company Capitainer AB and AstraZeneca Collaborate for Better Biomarkers

Revolutionary Partnership

Swedish medtech company, Capitainer AB, and AstraZeneca have joined forces to revolutionize the way clinical research is conducted in the pharmaceutical industry. Capitainer AB, with its novel device, will be collaborating with AstraZeneca R&D Gothenburg to develop protocols for biomarkers relevant to AstraZeneca’s clinical drug programs.

Remote Sampling Solutions

The collaboration aims to develop remote quantitative microsampling methods that will improve patient diversity, reduce the patient burden, and enable more frequent data collection to improve drug development decisions. With Capitainer AB’s quantitative self-sampling product, patients can now self-sample blood from the comfort of their homes.

Cutting-Edge Technology

Capitainer is the first company to present a self-sampling product that separates cells from whole blood. The sampling card, Capitainer®CF (CellFree), automatically meters an exact volume of cell-free blood and transfers it to a paper disc, where it dries, making transportation back to the laboratory easier.

First Partner

Capitainer R&D Manager, Anna Ohlander, is excited to have AstraZeneca as the first partner to set up methods for Capitainer AB’s new product that will soon be announced to the market. With the new technology fully developed and production initiated, Ohlander is looking forward to improving remote sampling of analytes that require plasma/serum-like fluids.

Exciting Prospects

Tasso Miliotis, Associate Principal Scientist at AstraZeneca, says that remote microsampling in patients’ homes will permit the inclusion of underserved populations to improve patient diversity, reduce the patient burden, and enable more frequent data collection to improve drug development decisions. The partnership between Capitainer AB and AstraZeneca promises exciting prospects for the future of clinical trials.